PE20230839A1 - Agentes de union a lair-1 y metodos para su uso - Google Patents
Agentes de union a lair-1 y metodos para su usoInfo
- Publication number
- PE20230839A1 PE20230839A1 PE2022002982A PE2022002982A PE20230839A1 PE 20230839 A1 PE20230839 A1 PE 20230839A1 PE 2022002982 A PE2022002982 A PE 2022002982A PE 2022002982 A PE2022002982 A PE 2022002982A PE 20230839 A1 PE20230839 A1 PE 20230839A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr2
- cdr3
- seq
- cdr1
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Referido a un agente de union que se une especificamente al dominio extracelular del receptor 1 similar a inmunoglobulina asociado a leucocitos (LAIR-1), donde el agente es un anticuerpo o un fragmento de union al antigeno de este, que comprende (a) una region variable de cadena pesada (VH) que comprende una region determinante de complementariedad (CDR)1 de VH, una CDR2 de VH y una CDR3 de VH de la SEQ ID NO: 117, y una region variable de cadena ligera (VL) que comprende una CDR1 de (VL), una CDR2 de VL y una CDR3 de VL de la SEQ ID NO: 118; o (b) una region variable de cadena pesada que comprende una CDR1 de VH, una CDR2 de VH y una CDR3 de VH de la SEQ ID NO: 119, y una region variable de cadena ligera que comprende una CDR1 de VL, una CDR2 de VL y una CDR3 de VL de la SEQ ID NO: 120. Tambien se refiere a un polinucleotido que lo codifica, uno o mas vectores y celulas aisladas que comprenden dicho polinucleotido y una composicion farmaceutica que comprende dicho anticuerpo; siendo utiles para tratar el cancer, tales como cancer de pancreas, cancer de mama, mesotelioma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042299P | 2020-06-22 | 2020-06-22 | |
| US202063122877P | 2020-12-08 | 2020-12-08 | |
| PCT/US2021/038251 WO2021262597A2 (en) | 2020-06-22 | 2021-06-21 | Lair-1-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230839A1 true PE20230839A1 (es) | 2023-05-19 |
Family
ID=76959074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002982A PE20230839A1 (es) | 2020-06-22 | 2021-06-21 | Agentes de union a lair-1 y metodos para su uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220041711A1 (es) |
| EP (1) | EP4168451A2 (es) |
| JP (1) | JP2023532857A (es) |
| KR (1) | KR20230039640A (es) |
| CN (2) | CN116209676A (es) |
| AU (1) | AU2021296168A1 (es) |
| BR (1) | BR112022026284A2 (es) |
| CA (1) | CA3187944A1 (es) |
| CL (1) | CL2022003684A1 (es) |
| CO (1) | CO2022018537A2 (es) |
| IL (1) | IL299245A (es) |
| MX (1) | MX2022016544A (es) |
| PE (1) | PE20230839A1 (es) |
| TW (1) | TW202216768A (es) |
| WO (1) | WO2021262597A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230220076A1 (en) * | 2021-12-21 | 2023-07-13 | Ngm Biopharmaceuticals, Inc. | Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody |
| WO2023173091A1 (en) * | 2022-03-11 | 2023-09-14 | Ngm Biopharmaceuticals, Inc. | Osteoclast-associated ig-like receptor (oscar) and methods of use thereof |
| WO2023215829A1 (en) * | 2022-05-05 | 2023-11-09 | Amgen Inc. | Heteromultimer binding dll3 and cd3 |
| WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007102736A2 (en) * | 2006-03-08 | 2007-09-13 | Universitair Medisch Centrum Utrecht | Interfering in activation of an immune cell by influencing interaction of lair and collagen. |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| MX2015015037A (es) | 2013-05-02 | 2016-07-08 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). |
| DK3478713T3 (da) * | 2016-06-30 | 2022-06-20 | Prothena Biosciences Ltd | Sammensætninger til behandling af amyloidose |
| EP3562508A4 (en) * | 2017-01-02 | 2021-04-07 | The Board of Regents of The University of Texas System | ANTI-BODY ANTI-LAIR1 AND THEIR USES |
-
2021
- 2021-06-21 EP EP21742964.6A patent/EP4168451A2/en active Pending
- 2021-06-21 MX MX2022016544A patent/MX2022016544A/es unknown
- 2021-06-21 BR BR112022026284A patent/BR112022026284A2/pt unknown
- 2021-06-21 KR KR1020237000749A patent/KR20230039640A/ko unknown
- 2021-06-21 WO PCT/US2021/038251 patent/WO2021262597A2/en unknown
- 2021-06-21 CN CN202180050298.5A patent/CN116209676A/zh active Pending
- 2021-06-21 US US17/353,295 patent/US20220041711A1/en active Pending
- 2021-06-21 AU AU2021296168A patent/AU2021296168A1/en active Pending
- 2021-06-21 TW TW110122557A patent/TW202216768A/zh unknown
- 2021-06-21 CN CN202310748928.7A patent/CN116813777A/zh active Pending
- 2021-06-21 IL IL299245A patent/IL299245A/en unknown
- 2021-06-21 PE PE2022002982A patent/PE20230839A1/es unknown
- 2021-06-21 JP JP2022579047A patent/JP2023532857A/ja active Pending
- 2021-06-21 CA CA3187944A patent/CA3187944A1/en active Pending
-
2022
- 2022-12-21 CO CONC2022/0018537A patent/CO2022018537A2/es unknown
- 2022-12-21 CL CL2022003684A patent/CL2022003684A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116813777A (zh) | 2023-09-29 |
| CL2022003684A1 (es) | 2023-07-28 |
| JP2023532857A (ja) | 2023-08-01 |
| CN116209676A (zh) | 2023-06-02 |
| IL299245A (en) | 2023-02-01 |
| CA3187944A1 (en) | 2021-12-30 |
| KR20230039640A (ko) | 2023-03-21 |
| CO2022018537A2 (es) | 2023-03-07 |
| WO2021262597A9 (en) | 2022-06-02 |
| TW202216768A (zh) | 2022-05-01 |
| MX2022016544A (es) | 2023-04-05 |
| WO2021262597A3 (en) | 2022-02-24 |
| BR112022026284A2 (pt) | 2023-03-07 |
| AU2021296168A1 (en) | 2023-02-02 |
| US20220041711A1 (en) | 2022-02-10 |
| EP4168451A2 (en) | 2023-04-26 |
| WO2021262597A2 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| PE20180795A1 (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
| CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| JP2019535670A5 (es) | ||
| ES2572356T3 (es) | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| MY188237A (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| MX2021012171A (es) | Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos |